Drugs / abexiclib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07446686 | Apr 2026 → Apr 2027 expected | breast cancer | Guizhou Provincial People's Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | abexiclib | “The starting dose of CDK4/6i (abexiclib, oral) is 50 mg bid, and other dose levels are: 100 mg bid, 150 mg bid.” NCT07446686 ↗ |
| Action | Inhibit | “CDK4/6 inhibitor” NCT07446686 ↗ |
| Route | Oral | “abexiclib, oral” NCT07446686 ↗ |